View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Deal News
January 26, 2022

Acquisitions jump in clinical trial operations in H2

The highest value acquisition in 2021 was the $12.3m acquisition of Vifor Pharma by CSL.

By Data Journalism Team

In the second half of 2021, acquisitions increased significantly by 35% from the same period in 2020.

This marks an acceleration in growth from the 6.2% decrease in deals seen from the first six months of 2020 to the same period in 2021.

During this time, the region that saw the biggest increase in the number of deals was North America.

From the second half of 2020 to the second half of 2021, the largest regional increase in deals was also seen in North America.

The region saw a 50% increase in deals.

During second half of 2021, acquisitions accounted for 4.1% of deals taking place in the sector. This represents an increase from the figure of 1.2% in second half of 2020.

GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.

The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.

By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.

The highest value acquisition that took place in 2021 (where the deal value was known) was the $12.3m acquisition of Vifor Pharma by CSL.

The database states that the rationale behind this deal was as follows: "The transaction will enable Vifor Pharma to leverage CSL's global reach, balance sheet and capabilities to bring more products to patients within its key categories. The transaction also enables Vifor Pharma to accelerate growth in cardiovascular-metabolic, renal and transplant."

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU